




HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT 2022



PHRAMONGKUTKLAO HOSPITAL

ARMY MEDICAL DEPARTMENT
MINISTRY OF DEFENCE
THAILAND

PHRAMONGKUTKLAO HOSPITAL EXCELLENT CENTER OF CANCER CARE

2022

Title

Phramongkutkiao Hospital Cancer Registry
Report 2022

Editonal Board

Naiyarat Prasongsook, M.D.

Chairman of cancer Registry Committee,
Chairman Excellent Center of Cancer Care.

Kritsada Srithanaphakarangkul, M.D.

Chairman of Cancer of the Data
Information committee

Published by

Clinical Epidemiology Unit and Oncology
Department,

Phramongkutkiao Hospital

315 Chalermprakiet Building, Ratchawithi Road,
Ratchathewi District, Thung Phaya Thai
Subdistrict. Bangkok 10400

Tel. : 02763 3925, 02763 3047

Published

2024

Edition

Fifteenth

Physical

71 pages



EXCELLENT CENTER OF CANCER CARE

HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2022

Phramongkutklo Hospital
Royal Thai Army Medical Department
Ministry of Defence
Bangkok, Thailand

Edited By
Y. Tanapat and K. Srithanaphakarangkul

Edition : December 2022

MESSAGE FROM DIRECTOR OF PHRAMONGKUTKLAO HOSPITAL



The Phramongkutklao Hospital is proud to present the Cancer Registry Report 2022. The report collects information on all new cancer cases. Data collected include the clinical characteristics of the cancer (site, histology, behavior, grade, extent of disease) and treatment details on the cancer patient. The registry has a comprehensive quality assurance program in place to ensure that the data are complete, accurate and timely.

I would like to thank all our collaborators for their dedication in providing data presented in this volume. I would like to express my gratitude to the devoted staffs of cancer registry in all cancer units for the immense amount of work that has been done in preparation of the statistics and graphics for this volume.

Thamrongroj Temudom Maj. Gen.
Director General of Phramongkutklao Hospital




INTRODUCTION

The Phramongkutklao Hospital Cancer Registry Report 2022 is a hospital-based cancer registry of new cancer patients initially diagnosed or initially treated at Phramongkutklao Cancer Center from January 1, 2022, to December 31, 2022. All new cancer patients registered during the mentioned period were treated at the various Cancer Units under The Excellent center of Cancer Care, Phramongkutklao Hospital. Patients were either primarily diagnosed or referred from army hospitals (under supervision of the Royal Thai Army Medical Department) as well as public and private hospitals. The objective of this is to report new cancer patients regarding method of diagnosis, pathological types, staging, behavior, grading, extension, and primary treatment modalities. Phramongkutklao Hospital has initiated a hospital cancer registry system based on the existing hospital data management system since 2009. This system has enabled physicians and nurses taking care of cancer patients to update patient information on the cancer registry at Cancer Units on a real-time basis. Thus, information obtained can be corrected and updated by persons in charge of patient care at the time of the patient's hospital visit. This process should contribute to the validity of information in the Cancer Registry.

This Cancer Registry Report would not be possible without the dedicated input of data from the staff of the Cancer Clinics and the Cancer Units from different departments at Phramongkutklao Cancer Center.



Assist. Prof. Naiyarat Prasongsook, M.D., M.S., COL.
Chairman Cancer Registry Committee
Phramongkutklao Cancer Center



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

1.	Maj.Gen.Thamrongroj	Temudom	Consultant
2.	Col. Pariyanan	Jaruchinda	Consultant
3.	Col. Rachata	Lumkul	Consultant
4.	Col. Kasan	Seetalarom	Consultant
5.	Col. Naiyarat	Prasongsook	Chairman of Administor Committee
6.	Col. Sukchai	Satthaporn.	Member
7.	Col. Chinakrit	BoonyaUssadorn	Member
8.	Col. Satit	Siriboonrid	Member
9.	Col. Sirinthip	Songwutwichai	Member
10.	Col. Chanchai	Traivaree	Member
11.	Col. Phutsapong	Srisawat	Member
12.	Lt.Col. Sithapan	Munjupong	Member
13.	Col. Kristsanamon	Rittiluechai	Member
14.	Lt.Col. Chonlada	Laoruagroj	Member
15.	Col. Vana	Sangsasri	Member
16.	Lt.Col. Jarey	Ketsirichai	Member
17.	Lt.Col. Siriwimon	Saichaemchan	Member
18.	Lt.Col. Watcharaporn	bourchom	Member
19.	Lt.Col. Kanya	Ketkong	Member
20.	Lt.Col. Nattapoang	Binsri	Member
21.	Lt.Col. Chalinee	Monseereenusorn	Member
22.	Lt.Col. Usa	Rittitada	Member
23.	Lt.Col. Supicha	Wongphun	Member



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

24.	Lt.Col. Kannadit	Prayongratana	Member
25.	Maj. Suvicha	Khampunnip	Member
26.	Maj. Sujitra	Shoolerd	Member
27.	Maj. Weerawan	Kaesai	Member
28.	Maj. Piyanuch	Srisuk	Member
29.	Maj. Nongnut	Seedapalee	Member
30.	Lt.Col. Rapeeporn	Kanchanapachana	Member
31.	Maj. Chetsuda	Khwanakorn	Member
32.	Capt. Sutipat	Pairojboriboon	Member
33.	Lt. Chatchanin	Ajalanond	Member
34.	Dr. Panjawit	Wuttipanich	Member
35.	Maj. wanvipa	Malaithong	Member
36.	Capt. Supittha	Tongpit	Member
37.	Maj. Phapasi	Punphasoed	Member
38.	Col. Jariya	Ketkaeo	Member
39.	Col. Waniknan	Hatsadin	Member
40.	Capt. Patcharaporn	liamsuwan	Member
41.	Capt. Atcharaporn	Sittichai	Member

CANCER REGISTRY STAFF

1.	Miss Rungthip	Boonyai	B.Com. (Computer)
2.	Miss Chawanphat	Udomphon	B.Sc. (Statistics)



TABLE OF CONTENTS

Title		
List of tables:		Page
Table 1	Distribution of new cancer patients by gender: 2022	1
Table 2	Number of all new patients: 2011-2022	2
Table 3	Ten leading primary sites of new cancer patients by gender: 2022	3
Table 4	Ten leading primary sites of new cancer patients in male: 2022	4
Table 5	Ten leading primary sites of new cancer patients in female: 2022	5
Table 6	Distribution of new cancer patients by age group and gender: 2022	6
Table 7	Distribution of new cancer patients by stage and gender: 2022	7
Table 8	Histologic differentiation of all solid cancer: 2022	8
Table 9	Immunophenotype designation for lymphomas and leukaemia: 2022	9
Table 10	Distribution of new cancer patients by extension and gender: 2022	9
Table 11	Distribution of new cancer patients by method and gender: 2022	10
Table 12	Distribution of new cancer patients by treatment modalities and gender: 2022	11
Table 13	Distribution of new cancer patients by treatment unit and gender: 2022	12
Table 14	Distribution of new cancer patients by status 2022	13
Table 15	Distribution of new cancer patients by follow up status and gender 2022	13
Table 16	Distribution of new military personnel cancer patients by age group and gender: 2022	14
Table 17	Distribution of new cancer patients by rank and gender: 2022	15
Table 18	Distribution of new childhood cancer patients (age 0-19) by age group and gender: 2022	16
Table 19	Distribution of new childhood cancer patients (age 0-19) by primary sites: 2022	16
Table 20	Distribution of new childhood cancer patients (age 0-19) by treatment modalities and gender: 2022	17
Table 21	Distribution of new childhood cancer patients (age 0-19) by method and gender: 2022	17
Table 22	Distribution of new childhood cancer patients (age 0-19) by type of extension and gender: 2022	18
Table 23	Distribution of new childhood cancer patients (age 0-19) by follow up and gender: 2022	18
Table 24	Number of new cancer patient stage and gender: 2022	19

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 1-3		
1. Colon and rectum cancer		
Table 25	Trend of colon and rectum cancer in Phramongkutklao hospital: 2011-2022	26
Table 26	Distribution of new colon and rectum cancer patients by age group and gender: 2022	27
Table 27	Distribution of new colon and rectum cancer patients by stage and gender: 2022	28
Table 28	Distribution of new colon and rectum cancer patients by method and gender: 2022	29
Table 29	Distribution of new colon and rectum cancer patients by extension and gender: 2022	29
Table 30	Distribution of new colon and rectum cancer patients by treatment modalities and gender: 2022	30
Table 31	Distribution of new colon and rectum cancer patients by follow up status and gender: 2022	30
2. Breast cancer		
Table 32	Trend of breast cancer in Phramongkutklao hospital: 2011-2022	31
Table 33	Distribution of new breast cancer patients by age group and gender : 2022	32
Table 34	Distribution of new breast cancer patients by stage and gender: 2022	33
Table 35	Distribution of new breast cancer patients by method and gender: 2022	34
Table 36	Distribution of new breast cancer patients by extension and gender : 2022	34
Table 37	Distribution of new breast cancer patients by treatment modalities and gender: 2022	35
Table 38	Distribution of new breast cancer patients by follow up status and gender: 2022	35
3. Trachea, bronchus, and lung cancer		
Table 39	Trend of trachea, bronchus, and lung cancer in Phramongkutklao hospital: 2011-2022	36
Table 40	Distribution of new trachea, bronchus and lung cancer patients by age group and gender: 2022	37
Table 41	Distribution of new trachea, bronchus and lung cancer patients by stage and gender: 2022	38
Table 42	Distribution of new trachea, bronchus and lung cancer patients by method and gender: 2022	39
Table 43	Distribution of new trachea, bronchus and lung cancer patients by extension and gender: 2022	39
Table 44	Distribution of new trachea, bronchus and lung cancer patients by treatment modalities and gender : 2022	40
Table 45	Distribution of new trachea, bronchus, and lung cancer patients by follow up status and gender: 2022	40

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 4-6		
4. PROSTATE GLAND		
Table 46	Distribution of new Prostate gland cancer patients by age group and gender: 2022	41
Table 47	Distribution of new Prostate gland cancer patients by stage and gender: 2022	42
Table 48	Distribution of new Prostate gland cancer patients by method and gender: 2022	43
Table 49	Distribution of new Prostate gland cancer patients by extension and gender: 2022	43
Table 50	Distribution of new Prostate gland cancer patients by treatment modalities and gender: 2022	44
Table 51	Distribution of new Prostate gland cancer patients by follow up status and gender: 2022	44
5. Liver and intrahepatic bile ducts cancer		
Table 52	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2022	45
Table 53	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2022	46
Table 54	Distribution of new Liver and intrahepatic bile ducts cancer patients by method and gender: 2022	47
Table 55	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2022	47
Table 56	Distribution of new Liver and intrahepatic bile ducts cancer patients by treatment modalities and gender: 2022	48
Table 57	Distribution of new Liver and intrahepatic bile ducts cancer patients by follow up status and gender : 2022	48
6. Thyroid cancer		
Table 58	Distribution of new Thyroid cancer patients by age group and gender : 2022	49
Table 59	Distribution of new Thyroid cancer patients by stage and gender : 2022	50
Table 60	Distribution of new Thyroid cancer patients by method and gender : 2022	51
Table 61	Distribution of new Thyroid cancer patients by extension and gender : 2022	51
Table 62	Distribution of new Thyroid cancer patients by treatment modalities and gender : 2022	52
Table 63	Distribution of new Thyroid cancer patients by follow up status and gender : 2022	52

TABLE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Table 64	Distribution of new cancer in male by age - group: 2022	53
Table 65	Distribution of new cancer in female by age - group: 2022	54
Distribution of new cancer in by morphology and site: 2022		
Table 66	Distribution of new cancer patients by morphology and site: 2022	55
Distribution of new cancer patients: 2018-2022		
Table 67	Distribution of new cancer patients by follow up and gender: 2018-2022	67
Table 68	The leading primary sites of new cancer by gender: 2018-2022	67
Table 69	The leading primary sites of new cancer by follow up and gender: 2018-2022	68
Table 70	The 60 months survival time (median) top 6 by gender in 2018 - 2022	68



FIGURE OF CONTENTS

Title		
List of figures:		Page
Figure 1	All new cancer cases in Phramongkutklao hospital :2011-2022	1
Figure 2	Trend of number of all new cancer patients by gender :2011-2022	2
Figure 3	Ten leading primary sites of new cancer patients by gender: 2022	3
Figure 4	Ten leading primary sites of new cancer patients in male: 2022	4
Figure 5	Ten leading primary sites of new cancer patients in female: 2022	5
Figure 6	Distribution of new cancer patients by age group and gender: 2022	6
Figure 7	Distribution of new cancer patients by stage and gender: 2022	7
Figure 8	Histologic differentiation of all solid cancer: 2022	8
Figure 9	Distribution of new cancer patients by extension and gender: 2022	9
Figure 10	Distribution of new cancer patients by method and gender: 2022	10
Figure 11	Distribution of new cancer patients by treatment unit and gender: 2022	12
Figure 12	Distribution of new cancer patients by follow up status: 2022	13
Figure 13	Distribution of new military personnel cancer patients by age group and gender: 2022	14
Figure 14	Distribution of new cancer patients by rank and gender: 2022	15



FIGURE OF CONTENTS

Title		
List of figures:		Page
Description of the leading site of cancers ordinal 1-3		
1. Colon and rectum cancer		
Figure 15	Distribution of new colon and rectum cancer patients by age group and gender: 2022	27
Figure 16	Distribution of new colon and rectum cancer patients by stage and gender: 2022	28
Figure 17	Distribution of new colon and rectum cancer patients by extension and gender: 2022	29
2. Breast cancer		
Figure 18	Distribution of new breast cancer patients by age group and gender : 2022	32
Figure 19	Distribution of new breast cancer patients by stage and gender: 2022	33
Figure 20	Distribution of new breast cancer patients by extension and gender : 2022	34
3. Trachea, bronchus, and lung cancer		
Figure 21	Distribution of new trachea, bronchus and lung cancer patients by age group and gender: 2022	37
Figure 22	Distribution of new trachea, bronchus and lung cancer patients by stage and gender: 2022	38
Figure 23	Distribution of new trachea, bronchus and lung cancer patients by extension and gender: 2022	39
4. Prostate gland		
Figure 24	Distribution of new Prostate gland cancer patients by age group and gender: 2022	41
Figure 25	Distribution of new Prostate gland cancer patients by stage and gender: 2022	42
Figure 26	Distribution of new Prostate gland cancer patients by extension and gender: 2022	43
5. Liver and intrahepatic bile ducts cancer		
Figure 27	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2022	45
Figure 28	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2022	46
Figure 29	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2022	47
6. NON-HODGKIN'S LYMPHOMA		
Figure 30	Distribution of new Non - Hodgkin's Lymphoma cancer patients by age group and gender: 2022	49
Figure 31	Distribution of new Non - Hodgkin's Lymphoma cancer patients by stage and gender: 2022	50
Figure 32	Distribution of new Non - Hodgkin's Lymphoma cancer patients by extension and gender: 2022	51

FIGURE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Distribution of the 60-month survival rate of cancers in : 2018-2022		
Figure 32	The 60 months survival rate (top 6) in 2018 – 2022	69
Figure 33	The 60 months survival rate (top 6) by male in 2018 – 2022	70
Figure 34	The 60 months survival rate (top 6) by Female in 2018 – 2022	71




2022 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 1 DISTRIBUTION OF NEW CANCER PATIENTS BY GENDER : 2022	
Type of patients	Number of cases
Total new hospital patients	47,768 (100.0%)
Total new cancer patients	1,702 (3.6%)
Gender distribution of cancer	
• Male	822 (48.3%)
• Female	880 (51.7%)

FIGURE 1: ALL NEW CANCER CASE IN PHRAMONGKUTKLOA HOSPITAL: 2011 – 2022



**TABLE 2** NUMBER OF ALL NEW PATIENTS : 2011 – 2022

Years	New patient	New cancer case	Case	Male		Female	
	Number	Number	Percent	Number	Percent	Number	Percent
2553 (2010)	50,148	1,730	3.45	927	1.85	803	1.60
2554 (2011)	58,244	1,898	3.26	985	1.69	913	1.57
2555 (2012)	66,151	1,801	2.72	897	1.36	904	1.37
2556 (2013)	68,306	1,856	2.72	947	1.39	909	1.33
2557 (2014)	55,484	1,536	2.77	801	1.44	735	1.32
2558 (2015)	59,191	1,771	2.99	881	1.49	890	1.50
2559 (2016)	58,320	1,539	2.64	779	1.34	760	1.30
2560 (2017)	55,771	1,666	2.99	886	1.59	780	1.40
2561 (2018)	57,049	1,720	3.01	885	1.55	835	1.46
2562 (2019)	42,412	1,608	3.79	800	1.89	808	1.91
2563 (2020)	46,210	1,526	3.30	771	1.67	755	1.63
2564 (2021)	47,768	1,702	3.56	822	1.72	880	1.84


FIGURE 2: TREND OF NUMBER OF ALL NEW PATIENTS BY GENDER: 2011 – 2022



TABLE 3 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER : 2022							
Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Colon & Rectum	140	17.0	95	10.8	235	13.8
2	Breast	5	0.3	221	25.1	226	13.3
3	Trachea, bronchus & lung	111	13.5	97	11.0	208	12.2
4	Prostate gland	114	13.9	0	0.0	114	6.7
5	Liver & intrahepatic bile ducts	79	9.6	25	2.8	104	6.1
6	Thyroid gland	18	2.2	85	9.7	103	6.0
7	Non-Hodgkin's lymphoma	30	3.6	31	3.5	61	3.6
8	Skin	25	3.0	33	3.8	58	3.4
9	Cervix	0	0.0	52	5.9	52	3.1
10	leukaemia	24	2.9	23	2.6	47	2.8

FIGURE 3: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER: 2022






TABLE 4 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE : 2022			
Ordinal	Primary site	Number	Percent
1	Colon & Rectum	140	17.03
2	Prostate gland	114	13.87
3	Trachea, bronchus & lung	111	13.50
4	Liver & intrahepatic bile ducts	79	9.61
5	Non-Hodgkin's lymphoma	30	3.65
6	Bladder	28	3.41
7	Kidney, renal pelvis & ureter	26	3.16
8	Skin	25	3.04
9	leukaemia	24	2.92
10	Lip & Oral cavity	21	2.55

FIGURE 4: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE: 2022







TABLE 5		TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE : 2022	
Ordinal	Primary site	Number	Percent
1	Breast	221	25.11
2	Trachea, bronchus & lung	97	11.02
3	Colon & Rectum	95	10.80
4	Thyroid gland	85	9.66
5	Cervix	52	5.91
6	Corpus uteri	43	4.89
7	Skin	33	3.75
8	Non-Hodgkin's lymphoma	31	3.52
9	Ovary	28	3.18
10	Liver & intrahepatic bile ducts	25	2.84

FIGURE 5: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE: 2022





Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	3	0.4	1	0.1	4	0.2
5 – 9	0	0.0	0	0.0	0	0.0
10 – 14	5	0.6	3	0.3	8	0.5
15 – 19	0	0.0	2	0.2	2	0.1
20 – 24	19	2.3	6	0.7	25	1.4
25 – 29	9	1.1	25	2.8	34	2.0
30 – 34	12	1.5	26	3.0	38	2.2
35 – 39	19	2.3	40	4.5	59	3.5
40 – 44	32	3.9	49	5.6	81	4.8
45 – 49	48	5.8	80	9.2	128	7.5
50 – 54	61	7.4	99	11.3	160	9.4
55 – 59	99	12.0	98	11.1	197	11.6
60 – 64	125	15.3	107	12.2	232	13.6
65 – 69	106	12.9	108	12.3	214	12.6
70 – 74	105	12.8	90	10.2	195	11.5
75 – 79	79	9.6	61	6.9	140	8.2
80 – 84	52	6.3	46	5.2	98	5.8
85 +	48	5.8	39	4.4	87	5.1
Total	822	100.0	880	100.0	1702	100.0

Majority of cases

FIGURE 6: DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER: 2022







TABLE 7	DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER : 2022					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	144	17.5	268	30.4	412	24.2
Stage II	201	24.5	191	21.7	392	23.1
Stage III	180	21.9	188	21.4	368	21.6
Stage IV	270	32.8	204	23.2	474	27.8
No stage	23	2.8	25	2.8	48	2.8
Unknown	4	0.5	4	0.5	8	0.5
Total	822	100.0	880	100.0	1702	100.0

*No stage: manual system including leukaemia and brain

FIGURE 7: DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER: 2022





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2022

TABLE 8HISTOLOGIC DIFFERENTIATION OF ALL SOLID CANCER : 2022						
Grade	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Well differentiated	92	12.3	128	15.7	220	14.0
Moderately differentiated	202	27.0	241	29.5	443	28.3
Poorly differentiated	233	31.1	233	28.5	466	29.8
Undifferentiated	61	8.1	10	1.2	71	4.5
Differentiated not Determined	161	21.5	205	25.1	366	23.4
Total	749	100.0	817	100.0	1566	100.0

FIGURE 8: HISTOLOGIC DIFFERENTIATION OF ALL SOLID CANCER: 2022






TABLE 9		IMMUNOPHENOTYPE DESIGNATION FOR LYMPHOMAS AND LEUKAEMIAS : 2022				
Immunophenotype designation	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
T – Cell	29	39.7	28	44.4	57	41.9
B – Cell	41	56.2	35	55.6	76	55.9
NK Cell	3	4.1	0	0.0	3	2.2
Total	73	100.0	63	100.0	136	100.0

TABLE 10		DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER : 2022				
Extend	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	474	57.7	567	64.4	1041	61.2
Regional lymph nodes	135	16.4	136	15.5	271	15.9
Distant metastasis	213	25.9	177	20.1	390	22.9
Total	822	100.0	880	100.0	1702	100.0

FIGURE 9: DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER: 2022






TABLE 11 DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER : 2022

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	8	1.0	9	1.0	17	1.0
Histopathology or Cytology	686	83.5	787	89.4	1473	86.5
Endoscopy	6	0.7	4	0.5	10	0.6
Bone marrow examination	71	8.6	63	7.2	134	7.9
Tumor marker	51	6.2	17	1.9	68	4.0
Total	822	100.0	880	100.0	1702	100.0

FIGURE 10: DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER: 2022






TABLE 12.1 DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	273	33.2	295	33.5	568	33.4
Radiation	52	6.3	120	13.6	172	10.1
Chemotherapy	103	12.5	102	11.6	205	12.0
Hormone	0	0.0	2	0.2	2	0.1
Immunotherapy	17	2.1	8	0.9	25	1.4
Interventional	22	2.8	12	1.4	34	2.0
Surgery and Radiotherapy	30	3.6	41	4.8	71	4.2
Surgery and Chemotherapy	62	7.6	103	11.7	165	9.6
Surgery and Hormone	1	0.1	0	0.0	1	0.1
Surgery and Immunotherapy	1	0.1	3	0.3	4	0.2
Surgery and Interventional	0	0.0	1	0.1	1	0.1
Surgery and Supportive	0	0.0	1	0.1	1	0.1
Radiotherapy and Chemotherapy	36	4.5	18	2.1	54	3.1






TABLE 12.2

DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy and Hormone	1	0.1	1	0.1	2	0.1
Chemotherapy and Immunotherapy	16	1.9	10	1.1	26	1.5
Chemotherapy and Interventional	15	1.8	2	0.2	17	1.0
Surgery and Radiotherapy and Chemotherapy	20	2.5	20	2.4	40	2.4
Surgery and Radiotherapy and Immunotherapy	1	0.1	0	0.0	1	0.1
Surgery and Chemotherapy and Hormone	0	0.0	1	0.1	1	0.1
Surgery and Chemotherapy and Immunotherapy	1	0.1	3	0.3	4	0.2
Surgery and Chemotherapy and Interventional	2	0.2	0	0.0	2	0.1
Surgery and Chemotherapy and Supportive	1	0.1	2	0.2	3	0.2
Radiotherapy and Chemotherapy and Hormone	1	0.1	1	0.1	2	0.1



<div> <div>TABLE 12.3</div> <div>DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022</div> </div>						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiotherapy and Chemotherapy and Immunotherapy	2	0.2	1	0.1	3	0.2
Radiotherapy and Chemotherapy and Interventional	0	0.0	1	0.1	1	0.1
Radiotherapy and Hormone and Immunotherapy	1	0.1	0	0.0	1	0.2
Surgery and Radiotherapy and Chemotherapy and Immunotherapy	3	0.4	1	0.1	4	0.1
Counseling	161	19.6	131	14.9	292	17.2
Total	822	100.0	880	100	1702	100





TABLE 13

DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER : 2022

Treatment unit	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Medicine oncology	363	44.2	291	33.1	654	38.4
Surgery oncology	328	39.9	287	32.6	615	36.1
Ear Nose and Throat oncology	85	10.3	61	6.9	146	8.6
Gynecologic oncology	0	0.0	124	14.1	124	7.3
Radiotherapy oncology	33	4.0	107	12.1	140	8.3
Pediatric oncology	7	0.9	5	0.6	12	0.7
Orthopedics oncology	6	0.7	5	0.6	11	0.6
Total	822	100.0	880	100.0	1702	100.0

FIGURE 11: DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER: 2022






TABLE 14	DISTRIBUTION OF NEW CANCER PATIENTS BY STATUS : 2022					
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Military	287	34.9	46	5.2	333	19.6
Civilian	535	65.1	834	94.8	1369	80.4
Total	822	100.0	880	100.0	1702	100.0

TABLE 15	DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2022					
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	581	70.7	726	82.5	1307	76.8
Deaths	241	29.3	154	17.5	395	23.2
Total	822	100.0	880	100.0	1702	100.0

Survey: 31 December 2022

FIGURE 12: DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS: 2022






TABLE 16

DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER : 2022

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	4	1.5	1	2.3	5	1.5
25 – 29	0	0.0	3	6.5	3	0.9
30 – 34	2	0.7	2	4.3	4	1.2
35 – 39	1	0.3	3	6.5	4	1.2
40 – 44	5	1.7	3	6.5	8	2.4
45 – 49	7	2.5	4	8.7	11	3.3
50 – 54	8	2.8	7	15.2	15	4.6
55 – 59	34	11.8	5	10.9	39	11.7
60 – 64	54	18.8	4	8.7	58	17.4
65 – 69	39	13.6	3	6.5	42	12.6
70 – 74	36	12.5	0	0.0	36	10.8
75 – 79	30	10.5	5	10.9	35	10.5
80 – 84	33	11.5	4	8.7	37	11.1
85 +	34	11.8	2	4.3	36	10.8
Total	287	100.0	46	100.0	333	100.0

Majority of cases

FIGURE 13: DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER: 2022






TABLE 17

DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER : 2022

Rank	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Major General – General	71	24.7	4	8.7	75	22.6
Major – Colonel	83	28.9	25	54.3	108	32.4
Sub Lieutenant – Captain	89	31.0	12	26.1	101	30.3
Sergeant Major 3 rd - Sergeant Major 1 st	27	9.4	4	8.7	31	9.3
Private 1 st class – Sergeant	13	4.5	1	2.2	14	4.2
Enlisted Soldier	4	1.4	0	0.0	4	1.2
Total	287	99.9	46	100.0	333	100.0

FIGURE 14: DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER: 2022





TABLE 18

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY AGE GROUP AND GENDER : 2022

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	3	37.5	1	16.7	4	28.6
5 – 9	0	0.0	0	0.0	0	0.0
10 – 14	5	62.5	3	50.0	8	57.1
15 - 19	0	0.0	2	33.3	2	14.3
Total	8	100.0	6	100.0	14	100.0

TABLE 19

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0- 19) BY PRIMARY SITES : 2022

Ordinal	Primary site	Male	Female	Total	
		Number	Number	Number	Percent
1.	Adrenal gland	1	0	1	7.1
2.	Bone & articular cartilage	2	1	3	21.4
3.	Intrathoracic organs	1	0	1	7.1
4.	leukaemia	3	3	6	42.9
5.	Non-Hodgkin's lymphoma	1	1	2	14.4
6.	Thyroid gland	0	1	1	7.1
Total		8	6	14	100.0



TABLE 20	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TREATMENT MODALITES AND GENDER : 2022					
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	1	12.5	1	16.7	2	14.3
Chemotherapy	3	37.5	2	33.3	5	35.8
Surgery & Radiotherapy	1	12.5	2	33.3	3	21.4
Surgery & Chemotherapy	1	12.5	0	0.0	1	7.1
Surgery &Radiotherapy & Chemotherapy	1	12.5	0	0.0	1	7.1
Counseling	1	12.5	1	16.7	2	14.3
Total	8	100.0	6	100.0	14	100.0

TABLE 21	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY METHOD AND GENDER : 2022					
	Male		Female		Total	
Method of diagnosis	Number	Percent	Number	Percent	Number	Percent
Bone marrow	4	50.0	4	33.3	8	42.9
Histopathology or Cytology	4	50.0	2	66.7	6	57.1
Total	8	100.0	6	100.0	14	100.0





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2022

Spreading/Metastasis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	7	87.5	5	83.3	12	85.7
Distant metastasis	1	12.5	1	16.7	2	14.3
Total	8	100.0	6	100.0	14	100.0

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	7	87.5	5	83.3	12	85.7
Deaths	1	12.5	1	16.7	2	14.3
Total	8	100.0	6	100.0	14	100.0

Survey: 31 December 2022






TABLE 24		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2022								
Site		Sex		Stage						
				I	II	III	IV	No stage	Un known	Total
Adrenal gland		Male		-	1	-	2	0	-	3
		Female		-	0	-	0	1	-	1
		Total	(N)	-	1	-	2	1	-	4
			(%)	-	100.0	-	100.0	100.0	-	100.0
Anus & anus canal		Male		0	4	4	3	-	-	11
		Female		1	1	0	0	-	-	2
		Total	(N)	1	5	4	3	-	-	13
			(%)	100.0	100.0	100.0	100.0	-	-	100.0
Bladder		Male		10	8	8	2	-	0	28
		Female		2	1	0	2	-	1	6
		Total	(N)	12	9	8	4	-	1	34
			(%)	100.0	100.0	100.0	100.0	-	100.0	100.0
Bone & articular cartilage		Male		4	1	1	1	-	-	7
		Female		4	1	1	1	-	-	7
		Total	(N)	8	2	2	2	-	-	14
			(%)	100.0	100.0	100.0	100.0	-	-	100.0
Brain		Male		-	-	-	-	6	-	6
		Female		-	-	-	-	10	-	10
		Total	(N)	-	-	-	-	16	-	16
			(%)	-	-	-	-	100.0	-	100.0
Breast		Male		0	5	0	0	-	-	5
		Female		77	60	53	31	-	-	221
		Total	(N)	77	65	53	31	-	-	226
			(%)	100.0	100.0	100.0	100.0	-	-	100.0
Cervix		Male		0	0	0	0	-	-	0
		Female		15	14	20	3	-	-	52
		Total	(N)	15	14	20	3	-	-	52
			(%)	100.0	100.0	100.0	100.0	-	-	100.0



TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2022

Site	Sex		Stage					
			I	II	III	IV	No stage	Un known
Colon & Rectum	Male		17	41	31	50	-	1
	Female		9	21	30	35	-	0
	Total	(N)	26	62	61	85	-	1
		(%)	100.0	100.0	100.0	100.0	-	100.0
Corpus uteri	Male		0	0	0	0	-	-
	Female		22	5	11	7	-	-
	Total	(N)	22	5	11	7	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Female genital organs	Male		0	0	0	-	-	-
	Female		4	1	1	-	-	-
	Total	(N)	4	1	1	-	-	-
		(%)	100.0	100.0	100.0	-	-	-
Gall bladder & unspecified parts of biliary tract	Male		0	3	1	6	-	-
	Female		1	1	2	3	-	-
	Total	(N)	1	4	3	9	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Hodgkin's disease	Male		-	1	2	1	-	-
	Female		-	1	0	1	-	-
	Total	(N)	-	2	2	2	-	-
		(%)	-	100.0	100.0	100.0	-	-
Hypopharynx	Male		-	2	1	4	-	-
	Female		-	1	1	0	-	-
	Total	(N)	-	3	2	4	-	-
		(%)	-	100.0	100.0	100.0	-	-
Intrathoracic organs	Male		2	2	3	1	-	-
	Female		0	0	1	1	-	-
	Total	(N)	2	2	4	2	-	-
		(%)	100.0	100.0	100.0	100.0	-	-



TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2022

Site	Sex		Stage					
			I	II	III	IV	No stage	Un known
Kidney, renal pelvis & ureter	Male		3	5	6	12	-	-
	Female		2	3	2	1	-	-
	Total	(N)	5	8	8	13	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Larynx	Male		3	2	7	4	-	-
	Female		0	0	1	0	-	-
	Total	(N)	3	2	8	4	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Leukaemia	Male		1	4	2	1	15	1
	Female		3	0	1	3	14	2
	Total	(N)	4	4	3	4	29	3
		(%)	100.0	100.0	100.0	100.0	100.0	100.0
Lip & Oral cavity	Male		2	3	5	11	-	-
	Female		2	8	2	3	-	-
	Total	(N)	4	11	7	14	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Mesothelial & soft tissue	Male		4	4	4	0	-	-
	Female		2	7	4	1	-	-
	Total	(N)	6	11	8	1	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
multiple myeloma	Male		3	1	10	2	-	-
	Female		3	4	2	0	-	-
	Total	(N)	6	5	12	2	-	-
		(%)	100.	100.0	100.0	100.0	-	-
Nasal cavity & accessory sinuses	Male		3	0	-	3	-	-
	Female		1	1	-	1	-	-
	Total	(N)	4	1	-	4	-	-
		(%)	100.0	100.0	-	100.0	-	-



TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2022

Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Nasopharynx	Male		1	2	5	9	-	-	17
	Female		0	0	2	0	-	-	2
	Total	(N)	1	2	7	9	-	-	19
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Non-Hodgkin's lymphoma	Male		4	7	5	13	-	1	30
	Female		8	4	2	16	-	1	31
	Total	(N)	12	11	7	29	-	2	61
		(%)	100.0	100.0	100.0	100.0	-	100.0	100.0
Oesophagus	Male		-	4	4	9	-	-	17
	Female		-	0	0	2	-	-	2
	Total	(N)	-	4	4	11	-	-	19
		(%)	-	100.0	100.0	100.0	-	-	100.0
Oropharynx	Male		1	2	6	5	-	-	14
	Female		0	0	1	1	-	-	2
	Total	(N)	1	2	7	6	-	-	16
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Other and ill-defined digestive organs	Male		-	-	-	0	-	-	0
	Female		-	-	-	1	-	-	1
	Total	(N)	-	-	-	1	-	-	1
		(%)	-	-	-	100.0	-	-	100.0
Other endocrine glands and relate structures	Male		1	1	-	3	2	-	7
	Female		1	0	-	1	0	-	2
	Total	(N)	2	1	-	4	2	-	9
		(%)	100.0	100.0	-	100.0	100.0	-	100.0
Ovary	Male		0	0	0	0	-	-	0
	Female		9	4	8	7	-	-	28
	Total	(N)	9	4	8	7	-	-	28
		(%)	100.0	100.0	100.0	100.0	-	-	100.0



TABLE 24		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2022						
Site	Sex		Stage					
			I	II	III	IV	No stage	Un known
Pancreas	Male		4	3	0	6	-	-
	Female		4	3	2	7	-	-
	Total	(N)	8	6	2	13	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Prostate gland	Male		31	38	19	26	-	-
	Female		0	0	0	0	-	-
	Total	(N)	31	38	19	26	-	-
		(%)	100.0	100.0	100.0	100.	-	-
Pyriform sinus	Male		-	1	-	-	-	-
	Female		-	0	-	-	-	-
	Total	(N)	-	1	-	-	-	-
		(%)	-	100.0	-	-	-	-
Liver & intrahepatic bile ducts	Male		12	33	13	20	-	1
	Female		4	8	3	10	-	0
	Total	(N)	16	41	16	30	-	1
		(%)	100.0	100.0	100.0	100.0	-	100.0
Skin	Male		15	2	7	1	-	-
	Female		18	5	7	3	-	-
	Total	(N)	33	7	14	4	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Small intestine	Male		-	-	1	-	-	-
	Female		-	-	2	-	-	-
	Total	(N)	-	-	3	-	-	-
		(%)	-	-	100.0	-	-	-
Stomach	Male		0	2	4	2	-	-
	Female		3	2	4	9	-	-
	Total	(N)	3	4	8	11	-	-
		(%)	100.0	100.0	100.0	100.0	-	-



TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2022

Site	Sex		Stage					
			I	II	III	IV	No stage	Un known
Thyroid gland	Male		9	2	0	7	-	-
	Female		57	20	8	0	-	-
	Total	(N)	66	22	8	7	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Tonsil	Male		-	4	2	1	-	-
	Female		-	1	2	1	-	-
	Total	(N)	-	5	4	2	-	-
		(%)	-	100.0	100.0	100.0	-	-
Trachea, bronchus & lung	Male		13	11	25	62	-	-
	Female		16	13	15	53	-	-
	Total	(N)	29	24	40	115	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Without specification of site	Male		-	1	-	2	-	-
	Female		-	0	-	0	-	-
	Total	(N)	-	1	-	2	-	-
		(%)	-	100.0	-	100.0	-	-
Male genital organs	Male		1	1	4	1	-	-
	Female		0	0	0	0	-	-
	Total	(N)	1	1	4	1	-	-
		(%)	100.0	100.0	100.0	100.0	-	-
Eye & Meninges	Male		-	0	-	-	-	-
	Female		-	1	-	-	-	-
	Total	(N)	-	1	-	-	-	-
		(%)	-	100.0	-	-	-	-

DESCRIPTION OF THE LEADING SITES OF CANCERS

1. COLON & RECTUM

2. BREAST

3. TRACHEA, BRONCHUS AND LUNG

4. PROSTATE GLAND

5. LIVER AND INTRAHEPATIC BILE DUCTS

6. THYROID GLAND





1. COLON & RECTUM CANCER

TABLE 25

TREND OF COLON & RECTUM CANCER IN PHRAMONGKUTKLAO HOSPITAL :
2011 - 2022

Years	Number of patients		Total
	Male	Female	
2011	123	78	201
2012	146	78	224
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	140	95	235



COLON & RECTUM CANCER


TABLE 26

DISTRIBUTION OF COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER : 2022

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	0	0.0	0	0.0
30 – 34	0	0.0	1	1.1	1	0.5
35 – 39	1	0.7	3	3.2	4	1.7
40 – 44	7	5.0	2	2.1	9	3.8
45 – 49	8	5.7	4	4.2	12	5.2
50 – 54	10	7.1	7	7.3	17	7.2
55 – 59	15	10.7	14	14.7	29	12.3
60 – 64	17	12.1	7	7.3	24	10.2
65 – 69	19	13.7	20	21.1	39	16.6
70 – 74	27	19.3	14	14.7	41	17.4
75 – 79	15	10.7	9	9.5	24	10.2
80 – 84	11	7.9	9	9.5	20	8.5
85 +	10	7.1	5	5.3	15	6.4
Total	140	100.0	95	100.0	235	100.0

Majority of cases

FIGURE 15: DISTRIBUTION OF COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER: 2022






COLON & RECTUM CANCER

TABLE 27	DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER : 2022					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	17	12.1	9	9.5	26	11.1
Stage II	41	29.3	21	22.1	62	26.3
Stage III	31	22.2	30	31.6	61	26.0
Stage IV	50	35.7	35	36.8	85	36.2
Unknown	1	0.7	0	0.0	1	0.4
Total	140	100.0	95	100.0	235	100.0

FIGURE 16: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER: 2022





COLON & RECTUM CANCER

TABLE 28

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY METHOD AND GENDER : 2022


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	1	0.7	0	0.0	1	0.4
Histopathology or Cytology	135	96.4	92	96.8	227	96.6
Endoscopy	4	2.9	3	3.2	7	3.0
Total	140	100.0	95	100.0	235	100.0

TABLE 29

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER : 2022

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	66	47.1	39	41.1	105	44.7
Regional lymph nodes	26	18.6	24	25.3	50	21.3
Distant metastasis	48	34.3	32	33.6	80	34.0
Total	140	100.0	95	100.0	235	100.0

FIGURE 17: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER: 2022





COLON & RECTUM CANCER

TABLE 30

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	69	49.3	34	35.8	103	43.8
Radiotherapy	4	2.9	2	2.1	6	2.6
Chemotherapy	14	10.0	13	13.6	27	11.5
Interventional	0	0.0	1	1.1	1	0.4
Surgery & Chemotherapy	23	16.4	27	28.3	50	21.3
Radiotherapy & Chemotherapy	2	1.4	1	1.1	3	1.3
Chemotherapy and Immunotherapy	1	0.7	1	1.1	2	0.9
Surgery & Radiotherapy & Chemotherapy	6	4.3	3	3.2	9	3.8
Surgery and Chemotherapy and Supportive	0	0.0	1	1.1	1	0.4
Counseling	21	15.0	12	12.6	33	14.0
Total	140	100.0	95	100.0	235	100.0

TABLE 31

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2022

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	108	77.1	83	87.4	191	81.3
Deaths	32	22.9	12	12.6	44	18.7
Total	140	100.0	95	100.0	235	100.0


Survey: 31 December 2022



2. BREAST CANCER

TABLE 32 TREND OF BREAST CANCER IN PHRAMONGKUTKLAO HOSPITAL: 2011 - 2022

Years	Number of patients		Total
	Male	Female	
2011	0	219	219
2012	1	291	292
2013	1	285	286
2014	0	261	261
2015	2	197	199
2016	2	198	200
2017	5	166	171
2018	4	180	184
2019	3	206	209
2020	3	181	184
2021	2	210	212
2022	5	221	226





BREAST CANCER


TABLE 33

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY AGE GROUP AND GENDER : 2022

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	1	0.5	1	0.4
25 – 29	0	0.0	1	0.5	1	0.4
30 – 34	0	0.0	4	1.8	4	1.8
35 – 39	0	0.0	5	2.3	5	2.2
40 – 44	0	0.0	18	8.1	18	8.0
45 – 49	0	0.0	27	12.2	27	11.9
50 – 54	0	0.0	30	13.6	30	13.3
55 – 59	0	0.0	27	12.2	27	11.9
60 – 64	0	0.0	29	13.1	29	12.8
65 – 69	1	20.0	29	13.1	30	13.3
70 – 74	1	20.0	22	10.0	23	10.2
75 – 79	1	20.0	15	6.8	16	7.1
80 – 84	0	0.0	7	3.1	7	3.2
85 +	2	40.0	6	2.7	8	3.5
Total	5	100.0	221	100.0	226	100.0

Majority of cases

FIGURE 18: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY AGE GROUP AND GENDER: 2022






BREAST CANCER

TABLE34	DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER : 2022					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.0	77	34.8	77	34.1
Stage II	5	100.0	60	27.1	65	28.8
Stage III	0	0.0	53	24.1	53	23.5
Stage IV	0	0.0	31	14.0	31	13.6
Total	5	100.0	221	100.0	226	100.0

FIGURE 19: DISTRIBUTION OF NEW BREASTCANCER PATIENTS BY STAGE AND GENDER: 2022





BREAST CANCER

TABLE 35


DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY METHOD AND GENDER : 2022

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	3	1.4	3	1.3
Histopathology or Cytology	5	100.0	218	98.6	223	98.7
Total	5	100.0	221	100.0	226	100.0

TABLE 36

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER : 2022

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	5	100.0	128	57.9	133	58.9
Regional lymph nodes	0	0.0	62	28.1	62	27.4
Distant metastasis	0	0.0	31	14.0	31	13.7
Total	5	100.0	221	100.0	226	100.0

FIGURE 20: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER: 2022



BREAST CANCER

TABLE 37

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	2	40.0	72	32.6	74	32.7
Radiotherapy	0	0.0	39	17.5	39	17.3
Chemotherapy	0	0.0	19	8.6	19	8.4
Hormone	0	0.0	2	0.9	2	0.9
Surgery and Radiotherapy	1	20.0	13	5.9	14	6.2
Surgery and Chemotherapy	1	20.0	41	18.6	42	18.6
Surgery and Immunotherapy	0	0.0	1	0.5	1	0.4
Radiotherapy and Chemotherapy	0	0.0	3	1.3	3	1.3
Chemotherapy and Hormone	0	0.0	1	0.5	1	0.4
Chemotherapy and Immunotherapy	0	0.0	1	0.5	1	0.4
Surgery and Radiotherapy and Chemotherapy	0	0.0	5	2.2	5	2.3
Surgery and Chemotherapy and Hormone	0	0.0	1	0.5	1	0.4
Surgery and Chemotherapy and Immunotherapy	1	20.0	3	1.3	4	1.9
Surgery and Chemotherapy and Supportive	0	0.0	1	0.5	1	0.4
Surgery and Radiotherapy and Chemotherapy and Immunotherapy	0	0.0	2	1.0	2	0.8
Counseling	0	0.0	17	7.6	17	7.6
Total	5	100.0	221	100.0	226	100.0

TABLE 38

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2022

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	5	100.0	208	94.1	213	94.2
Deaths	0	0.0	13	5.9	13	5.8
Total	5	100.0	221	100.0	226	100.0



3. TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 39

TREND OF TRACHEA, BRONCHUS AND LUNG CANCER IN PHRAMONGKUTKLAO HOSPITAL: 2011 – 2022

Years	Number of patients		Total
	Male	Female	
2011	123	78	201
2012	146	78	224
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	111	97	208




TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 40	DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER : 2022					
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	2	1.8	1	1.0	3	1.4
30 – 34	1	0.9	1	1.0	2	1.0
35 – 39	3	2.7	2	2.1	5	2.4
40 – 44	3	2.7	3	3.1	6	2.9
45 – 49	6	5.4	4	4.1	10	4.8
50 – 54	6	5.4	12	12.4	18	8.7
55 – 59	18	16.2	9	9.4	27	13.0
60 – 64	18	16.2	11	11.3	29	13.9
65 – 69	18	16.2	21	21.6	39	18.8
70 – 74	12	10.8	15	15.5	27	13.0
75 – 79	13	11.7	8	8.2	21	10.1
80 – 84	9	8.2	6	6.2	15	7.1
85 +	2	1.8	4	4.1	6	2.9
Total	111	100.0	97	100.0	208	100.0

Majority of cases

FIGURE 21: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER: 2022






TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 41	DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER : 2022					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	13	11.7	16	16.5	29	13.9
Stage II	11	9.9	13	13.4	24	11.5
Stage III	25	22.5	15	15.5	40	19.3
Stage IV	62	55.9	53	54.6	115	55.3
Total	111	100.0	97	100.0	208	100.0

FIGURE 22: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER: 2022





TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 42

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY METHOD AND GENDER : 2022


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Endoscopy & Radiology	2	1.8	2	2.1	4	1.9
Histopathology or Cytology	109	98.2	95	97.9	204	98.1
Total	111	100.0	97	100.0	208	100.0

TABLE 43

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER : 2022

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	29	26.1	34	35.1	63	30.3
Regional lymph nodes	22	19.8	12	12.3	34	16.3
Distant metastasis	60	54.1	51	52.6	111	53.4
Total	111	100.0	97	100.0	208	100.0

FIGURE 23: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER: 2022





TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 44

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	35	31.5	36	37.1	71	34.1
Radiotherapy	7	6.3	6	6.2	13	6.3
Chemotherapy	11	9.9	8	8.3	19	9.1
Immunotherapy	2	1.8	2	2.1	4	1.9
Surgery & Radiotherapy	4	3.6	2	2.1	6	2.8
Surgery & Chemotherapy	6	5.4	6	6.2	12	5.8
Surgery and Hormone	1	0.9	0	0.0	1	0.5
Surgery & Immunotherapy	0	0.0	1	1.0	1	0.5
Radiotherapy & Chemotherapy	7	6.3	4	4.1	11	5.3
Chemotherapy & Immunotherapy	2	1.8	1	1.0	3	1.4
Surgery & Radiotherapy & Chemotherapy	3	2.7	1	1.0	4	1.9
Surgery & Chemotherapy & Supportive	1	0.9	0	0.0	1	0.5
Radiotherapy & Chemotherapy & Immunotherapy	1	0.9	1	1.0	2	1.0
Surgery & Radiotherapy & Chemotherapy & Immunotherapy	1	0.9	0	0.0	1	0.5
Counseling	30	27.0	29	29.9	59	28.4
Total	111	99.9	97	100.0	208	100.0

TABLE 45

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2022

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	66	59.5	57	58.8	123	59.1
Deaths	45	40.5	40	41.2	85	40.9
Total	111	100.0	97	100.0	208	100.0

Survey: 31 December 2022



4. PROSTATE GLAND CANCER


TABLE 46

DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER : 2022

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	0	0.0	0	0.0
30 – 34	0	0.0	0	0.0	0	0.0
35 – 39	0	0.0	0	0.0	0	0.0
40 – 44	0	0.0	0	0.0	0	0.0
45 – 49	0	0.0	0	0.0	0	0.0
50 – 54	2	1.8	0	0.0	2	1.8
55 – 59	8	7.0	0	0.0	8	7.0
60 – 64	20	17.5	0	0.0	20	17.5
65 – 69	20	17.5	0	0.0	20	17.5
70 – 74	25	21.9	0	0.0	25	21.9
75 – 79	19	16.7	0	0.0	19	16.7
80 – 84	10	8.8	0	0.0	10	8.8
85+	10	8.8	0	0.0	10	8.8
Total	114	100.0	0	0.0	114	100.0

Majority of cases

FIGURE 24: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER: 2022






PROSTATE GLAND CANCER

TABLE 47	DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER : 2022					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	31	27.2	0	0.0	31	27.2
Stage II	38	33.3	0	0.0	38	33.3
Stage III	19	16.7	0	0.0	19	16.7
Stage IV	26	22.8	0	0.0	26	22.8
Total	114	100.0	0	0.0	114	100.0

FIGURE 25: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER: 2022





PROSTATE GLAND CANCER

TABLE 48

DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY METHOD AND GENDER : 2022


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	2	1.8	0	0.0	2	1.8
Histopathology or Cytology	112	98.2	0	0.0	112	98.2
Total	114	100.0	0	0.0	114	100.0

TABLE 49

DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER : 2022

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	86	75.4	0	0.0	86	75.4
Regional lymph nodes	7	6.1	0	0.0	7	6.1
Distant metastasis	21	18.5	0	0.0	21	18.5
Total	114	100.0	0	0.0	114	100.0

FIGURE 26: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER: 2022





PROSTATE GLAND CANCER

TABLE 50

DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	46	40.4	0	0.0	46	40.4
Radiotherapy	23	20.1	0	0.0	23	20.1
Chemotherapy	1	0.9	0	0.0	1	0.9
Interventional	1	0.9	0	0.0	1	0.9
Surgery & Radiotherapy	7	6.1	0	0.0	7	6.1
Surgery & Chemotherapy	1	0.9	0	0.0	1	0.9
Chemotherapy and Hormone	1	0.9	0	0.0	1	0.9
Radiotherapy and Hormone and Immunotherapy	1	0.9	0	0.0	1	0.9
Counseling	33	28.9	0	0.0	33	28.9
Total	114	100.0	0	0.0	114	100.0

TABLE 51

DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2022

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	105	92.1	0	0.0	105	92.1
Deaths	9	7.9	0	0.0	9	7.9
Total	114	100.0	0	0.0	114	100.0

Survey: 31 December 2022



5. LIVER AND INTRAHEPATIC BILE DUCTS
CANCER


TABLE 52

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER : 2022

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 20	0	0.0	0	0.0	0	0.0
21 – 24	1	1.3	0	0.0	1	1.0
25 – 29	0	0.0	0	0.0	0	0.0
30 – 34	2	2.5	0	0.0	2	1.9
35 – 39	1	1.3	1	4.0	2	1.9
40 – 44	4	5.1	1	4.0	5	4.8
45 – 49	7	8.8	1	4.0	8	7.7
50 – 54	6	7.6	1	4.0	7	6.7
55 – 59	14	17.7	3	12.0	17	16.3
60 – 64	20	25.3	5	20.0	25	24.1
65 – 69	6	7.6	4	16.0	10	9.6
70 – 74	9	11.4	2	8.0	11	10.6
75 – 79	4	5.1	1	4.0	5	4.8
80 – 84	5	6.3	5	20.0	10	9.6
85+	0	0.0	1	4.0	1	1.0
Total	79	100.0	25	100.0	104	100.0

Majority of cases

FIGURE 27: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER: 2022






LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 53	DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER : 2022					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	12	15.2	4	16.0	16	15.4
Stage II	33	41.8	8	32.0	41	39.4
Stage III	13	16.5	3	12.0	16	15.4
Stage IV	20	25.3	10	40.0	30	28.8
Unknown	1	1.2	0	0.0	1	1.0
Total	79	100.0	25	100.0	104	100.0

FIGURE 28: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER: 2022





LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 54

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY METHOD AND GENDER : 2022


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	29	36.7	8	32.0	37	35.6
Tumor marker	50	63.3	17	68.0	67	64.4
Total	79	100.0	25	100.0	104	100.0

TABLE 55

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER : 2022

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	65	82.3	16	64.0	81	77.9
Distant metastasis	14	17.7	9	36.0	23	22.1
Total	79	100.0	25	100.0	104	100.0

FIGURE 29: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER: 2022





LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 56

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2022

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	19	24.4	3	11.5	22	21.2
Chemotherapy	13	15.4	8	34.6	21	20.2
Immunotherapy	1	1.3	0	0.0	1	1.0
Interventional	19	24.4	7	26.9	26	25.0
Surgery & Chemotherapy	2	2.5	1	3.8	3	2.8
Surgery & Interventional	0	0.0	1	3.8	1	1.0
Radiotherapy & Chemotherapy	1	1.3	0	0.0	1	1.0
Chemotherapy & Interventional	15	19.2	2	7.8	17	16.3
Surgery & Radiotherapy & Immunotherapy	1	1.3	0	0.0	1	1.0
Surgery & Chemotherapy & Interventional	2	2.5	0	0.0	2	1.8
Radiotherapy & Chemotherapy & Interventional	0	0.0	1	3.8	1	1.0
Counseling	6	7.7	2	7.8	8	7.7
Total	79	100.0	25	100.0	104	100.0

TABLE 57

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2022

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	39	49.4	14	56.0	53	51.0
Deaths	40	50.6	11	44.0	51	49.0
Total	79	100.0	25	100.0	104	100.0

Survey: 31 December 2022



6. THYROID GLAND CANCER


TABLE 58

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY AGE GROUP IN MALE : 2022

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 14	0	0.0	0	0.0	0	0.0
15 – 19	0	0.0	1	1.2	1	1.0
20 – 24	1	5.6	2	2.4	3	2.9
25 – 29	0	0.0	14	16.4	14	13.6
30 – 34	2	11.1	8	9.4	10	9.7
35 – 39	2	11.1	12	14.1	14	13.6
40 – 44	2	11.1	8	9.4	10	9.7
45 – 49	2	11.1	9	10.5	11	10.7
50 – 54	2	11.1	11	12.9	13	12.6
55 – 59	0	0.0	6	7.1	6	5.8
60 – 64	3	16.7	4	4.7	7	6.8
65 – 69	1	5.6	1	1.2	2	1.9
70 – 74	3	16.7	5	5.9	8	7.9
75 – 79	0	0.0	2	2.4	2	1.9
80 – 84	0	0.0	0	0.0	0	0.0
85 +	0	0.0	2	2.4	2	1.9
Total	18	100.0	85	100.0	103	100.0

Majority of cases

FIGURE 30: DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY AGE GROUP IN MALE: 2022






THYROID GLAND CANCER

Staging	DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY STAGE IN MALE: 2022					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	9	50.0	57	67.1	66	64.1
Stage II	2	11.1	20	23.5	22	21.3
Stage III	0	0.0	8	9.4	8	7.8
Stage IV	7	38.9	0	0.0	7	6.8
Total	18	100.0	85	100.0	103	100.0

FIGURE 31: DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY STAGE IN MALE: 2022





THYROID GLAND CANCER

TABLE 60

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY METHOD IN MALE : 2022


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	18	100.0	85	100.0	103	100.0
Total	18	100.0	85	100.0	103	100.0

TABLE 61

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY EXTENSION IN MALE : 2022

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	9	50.0	79	92.9	88	85.4
Regional lymph nodes	3	16.7	6	7.1	9	8.8
Distant metastasis	6	33.3	0	0.0	6	5.8
Total	18	100.0	85	100.0	103	100.0

FIGURE 32: DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY EXTENSION IN MALE: 2022



**THYROID GLAND CANCER****TABLE 62****DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT MODALITIES IN MALE: 2022**

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	5	27.8	17	20.0	22	21.4
Radiotherapy	6	33.3	38	44.7	44	42.6
Chemotherapy	1	5.5	0	0.0	1	1.0
Surgery & Radiotherapy	3	16.7	14	16.5	17	16.5
Surgery & Chemotherapy	0	0.0	1	1.2	1	1.0
Counseling	3	16.7	15	17.6	18	17.5
Total	18	100.0	85	100.0	103	100.0

TABLE 63**DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY FOLLOW UP STATUS IN MALE: 2022**

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	18	100.0	82	96.5	100	97.1
Deaths	0	0.0	3	3.5	3	2.9
Total	18	100.0	85	100.0	103	100.0

Survey: 31 December 2022



2022 HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT



● MALE ●

TABLE 64		DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2022																		
ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84	
C00-C08	Oral cavity	21	0	0	0	0	0	0	0	0	2	2	4	3	3	4	1	0	2	0
C01,C05,C10	Oropharynx	14	0	0	0	0	0	0	1	0	1	0	3	5	0	0	3	1	0	0
C09	Tonsil	7	0	0	0	0	0	0	0	0	2	1	0	3	0	1	0	0	0	0
C11	Nasopharynx	17	0	0	0	0	1	0	0	0	1	4	1	3	2	2	1	1	1	0
C12-C13	Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C14	Pharynx	7	0	0	0	0	0	0	0	1	0	1	3	0	1	1	0	0	0	0
C15	Esophagus	17	0	0	0	0	0	0	0	0	1	0	2	4	4	4	1	0	1	0
C16	Stomach	8	0	0	0	0	2	0	0	0	0	1	0	1	0	1	1	1	0	1
C17	Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C18-C20	Colon and Rectum	140	0	0	0	0	0	0	0	1	7	8	10	15	17	19	27	15	11	10
C21	Anus	11	0	0	0	0	0	0	1	1	1	0	1	0	1	3	1	1	0	1
C22	Liver and Bile ducts	79	1	0	0	0	1	0	2	1	4	7	6	14	19	6	9	4	5	0
C23-C24	Gallbladder	10	0	0	0	0	0	0	0	1	0	1	1	1	3	0	0	0	3	0
C25	Pancreas	13	0	0	0	0	0	0	0	0	0	5	1	3	3	0	1	0	0	0
C30-C31	Nose, sinuses etc	6	0	0	0	0	0	1	1	0	0	2	1	0	0	0	0	0	0	1
C32	Larynx	16	0	0	0	0	0	0	0	0	0	0	4	0	2	5	2	2	0	1
C33-C34	Trachea, bronchus, lung	111	0	0	0	0	0	2	1	3	3	6	6	18	18	18	12	13	9	2
C37-C39	Other thoracic organs	8	0	0	1	0	3	1	0	0	0	0	0	1	1	1	0	0	0	0
C40-C41	Bone & joints	7	0	0	2	0	1	0	0	0	2	0	1	0	0	0	0	0	1	0
C43-C44	Melanoma of skin	25	0	0	0	0	0	1	1	0	0	0	0	1	0	1	3	6	2	10
C45-C49	Mesothelioma	12	0	0	0	0	0	0	0	0	0	2	1	3	2	3	1	0	0	0
C50	Breast	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2
C60, C62-C63	Male genital organs	7	0	0	0	0	2	1	1	0	1	2	0	0	0	0	0	0	0	0
C61	Prostate	114	0	0	0	0	0	0	0	0	0	0	2	8	20	20	25	19	10	10
C64-C66	Kidney & Ureter	26	0	0	0	0	0	0	0	1	0	1	6	5	5	2	2	1	2	1
C67	Bladder	28	0	0	0	0	0	0	0	0	2	0	1	0	9	2	2	7	1	4
C69-C70	Eye & Meninges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C71-C72	Brain	6	0	0	0	0	2	0	0	1	0	0	1	0	1	0	0	1	0	0
C73	Thyroid gland	18	0	0	0	0	1	0	2	2	2	2	2	0	3	1	3	0	0	0
C74	Adrenal gland	3	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0
C75	Other endocrine glands	7	0	0	0	0	0	0	0	2	0	0	1	1	1	1	1	0	0	0
C80	Without unspecified	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0
C81	Hodgkin's disease	4	0	0	0	0	1	1	1	0	0	0	0	0	0	1	0	0	0	0
C82 -C85,	Non-Hodgkin lymphoma	30	0	0	1	0	1	1	0	3	1	1	0	6	2	3	5	3	0	3
C90	Multiple myeloma	16	0	0	0	0	0	0	0	1	0	0	0	3	5	2	2	0	3	0
C91-C95	Leukemia	24	2	0	1	0	4	1	1	1	2	0	2	1	2	2	0	2	1	2
Total		822	4	0	5	0	19	9	12	19	32	48	61	99	124	106	105	79	52	48



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2022

● FEMALE ●

TABLE 65		DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2022																		
ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84	
C00-C08	Oral cavity	15	0	0	0	0	0	0	0	2	1	3	0	1	3	1	1	2	0	1
C01,C05,C10	Oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
C09	Tonsil	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0
C11	Nasopharynx	2	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0
C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
C15	Esophagus	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
C16	Stomach	18	0	0	0	0	0	0	1	1	1	2	4	0	1	4	0	2	0	2
C17	Small intestine	2	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0
C18-C20	Colon and Rectum	95	0	0	0	0	0	0	1	3	2	4	7	14	7	20	14	9	9	5
C21	Anus	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0
C22	Liver and Bile ducts	25	0	0	0	0	0	0	0	1	1	1	1	3	5	4	2	1	5	1
C23-C24	Gallbladder	7	0	0	0	0	0	0	0	0	0	0	2	1	2	0	1	1	0	0
C25	Pancreas	16	0	0	0	0	0	1	0	0	2	1	0	2	0	2	2	1	3	2
C30-C31	Nose, sinuses etc	3	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C33-C34	Trachea, bronchus, lung	97	0	0	0	0	0	1	1	2	3	4	12	9	11	21	15	8	6	4
C37-C39	Other thoracic organs	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
C40-C41	Bone	7	0	0	1	0	1	0	0	0	0	2	0	0	2	0	1	0	0	0
C43-C44	Melanoma of skin	33	0	0	0	0	0	0	1	1	0	0	0	4	2	3	5	7	4	6
C45-C49	Connective and soft tissue	14	0	0	0	0	0	0	0	1	1	3	2	1	0	3	3	0	0	0
C50	Breast	221	0	0	0	0	1	1	4	5	18	27	30	27	29	29	22	15	7	6
C51-C52, C57	Female genital organs	6	0	0	0	0	0	0	0	1	1	1	1	0	2	0	0	0	0	0
C53	Cervix uteri	52	0	0	0	0	0	2	5	4	2	7	10	7	6	0	3	3	2	1
C54	Corpus uteri	43	0	0	0	0	0	1	0	1	1	5	3	6	7	6	6	2	3	2
C55	Uterus	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0
C56	Ovary	28	0	0	0	0	1	0	0	0	3	5	6	4	4	2	0	1	0	2
C64-C66	Kidney & Ureter	8	0	0	0	0	0	0	1	0	0	0	0	1	2	0	2	1	0	1
C67	Bladder	6	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	2
C68	Other and unspecified urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C69-C70	Eye & Meninges	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C71-C72	Brain	10	0	0	0	0	0	1	0	2	1	0	2	2	1	0	0	1	0	0
C73	Thyroid gland	85	0	0	0	1	2	14	8	12	8	9	11	6	4	1	5	2	0	2
C74	Adrenal gland	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C78	other endocrine glands and relate structures	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0
C81	Hodgkin's disease	2	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0
C82 -C85	Non-Hodgkin lymphoma	31	0	0	0	1	1	0	2	2	2	1	2	5	4	4	5	1	0	1
C90	Multiple myeloma	9	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	3	3	0
C91-C95	Leukaemia	23	1	0	2	0	0	2	0	2	2	1	3	0	4	3	2	0	0	1
Total		880	1	0	3	2	6	25	26	40	49	80	99	98	107	108	90	61	46	39

2022 HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C00-C08, C14	Lip & Oral cavity		21	15	36
C020	8070/3	Squamous cell carcinoma, NOS	2	3	5
C021	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	4	1	5
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C0211	8010/3	Carcinoma, NOS	1	0	1
C022	8070/3	Squamous cell carcinoma, NOS	1	0	1
C023	8070/3	Squamous cell carcinoma, NOS	1	0	1
C024	8070/3	Squamous cell carcinoma, NOS	1	0	1
C029	8070/3	Squamous cell carcinoma, NOS	4	2	6
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
C031	8070/3	Squamous cell carcinoma, NOS	1	0	1
C07	8010/3	Carcinoma, NOS	0	3	3
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	1	2
C080	9680/3	Malignant lymphoma, large B-cell , diffuse, NOS	0	1	1
C089	8046/3	Non-small cell carcinoma	1	0	1
C140	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	2	1	3
C09	Tonsil		7	4	11
C090	8070/3	Squamous cell carcinoma, NOS	5	0	5
C099	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	2	3	5
C01, C05, C10	Oropharynx etc.		14	2	16
C01	8070/3	Squamous cell carcinoma, NOS	4	0	4
C050	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C051	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
C059	8070/3	Squamous cell carcinoma, NOS	0	1	1
	9520/3	Olfactory neurogenic tumor	1	0	1
C103	8070/3	Squamous cell carcinoma, NOS	1	0	1
C109	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8071/3	Squamous cell carcinoma, keratinizing, NOS	2	0	2
C11	Nasopharynx		17	2	19
C110	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
C113	8070/3	Squamous cell carcinoma, NOS	0	1	1
C119	8010/3	Carcinoma, NOS	4	0	4
	8070/3	Squamous cell carcinoma, NOS	4	1	5
	8070/6	Squamous cell carcinoma, metastatic, NOS	2	0	2
	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	2	0	2
	8073/6	Squamous cell carcinoma, small cell, nonkeratinizing, metastatic	2	0	2



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2022

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C12	Pyriform sinus				
C129	8070/3	Squamous cell carcinoma, NOS	1	0	1
C13	Hypopharynx		7	2	9
C130	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
C131	8070/3	Squamous cell carcinoma, NOS	2	0	2
C132	8070/3	Squamous cell carcinoma, NOS	1	0	1
C139	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	1	3
C15	Esophagus		17	2	19
C151	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8070/6	Squamous cell carcinoma, metastatic, NOS	4	0	4
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C153	8070/3	Squamous cell carcinoma, NOS	1	0	1
C154	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C155	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C159	8070/3	Squamous cell carcinoma, NOS	3	1	4
	8140/3	Adenocarcinoma, NOS	1	0	1
C16	Stomach		8	18	26
C160	8010/3	Carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	2	3
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C161	8140/3	Adenocarcinoma, NOS	1	0	1
C162	8010/3	Carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	1	4	5
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
C163	8140/3	Adenocarcinoma, NOS	1	1	2
C169	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8074/6	Squamous cell carcinoma, spindle cell, metastatic	1	0	1
	8140/3	Adenocarcinoma, NOS	2	2	4
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
	9764/3	Immunoproliferative small intestinal disease	0	1	1
C17	Small intestine		1	2	3
C171	9764/3	Immunoproliferative small intestinal disease	0	1	1
C172	8246/3	Neuroendocrine carcinoma, NOS	0	1	1
	8770/3	Mixed epithelioid and spindle cell melanoma	1	0	1


TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C18-C20	Colon & Rectum		135	92	227
C180	8010/3	Carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	2	7	9
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C181	8140/3	Adenocarcinoma, NOS	0	1	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C182	8140/3	Adenocarcinoma, NOS	1	5	6
	8140/6	Adenocarcinoma, metastatic, NOS	1	4	5
C183	8140/3	Adenocarcinoma, NOS	8	2	10
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C184	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	3	6	9
	8140/6	Adenocarcinoma, metastatic, NOS	2	1	3
C185	8140/3	Adenocarcinoma, NOS	2	2	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C186	8140/3	Adenocarcinoma, NOS	3	5	8
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
	8850/3	Liposarcoma, NOS	1	0	1
C187	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	35	23	58
	8140/6	Adenocarcinoma, metastatic, NOS	12	5	17
	8263/3	Adenocarcinoma in tubulovillous adenoma	1	0	1
C188	8140/3	Adenocarcinoma, NOS	1	0	1
C189	8140/3	Adenocarcinoma, NOS	9	4	13
	8140/6	Adenocarcinoma, metastatic, NOS	6	1	7
C19	8140/3	Adenocarcinoma, NOS	1	2	3
	8140/6	Adenocarcinoma, metastatic, NOS	2	1	3
C20	8010/3	Carcinoma, NOS	2	0	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	32	11	43
	8140/6	Adenocarcinoma, metastatic, NOS	5	5	10
	8890/3	Leiomyosarcoma, NOS	0	1	1
C21	Anus & Anus canal		9	2	11
C210	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C218	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	4	0	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C22	Liver & Intrahepatic bile ducts		38	13	51
C220	8010/3	Carcinoma, NOS	5	0	5
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	1	2
	8160/6	Cholangiocarcinoma, metastatic	0	1	1



HOSPITAL-BASED CANCER REGISTRY 2022

ANNUAL REPORT

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C221	8170/3	Hepatocellular carcinoma, NOS	21	4	25
	8170/6	Hepatocellular carcinoma, metastatic, NOS	2	0	2
	8174/3	Hepatocellular carcinoma, clear cell type	1	0	1
	8010/3	Carcinoma, NOS	1	1	2
	8140/3	Adenocarcinoma, NOS	2	1	3
	8140/6	Adenocarcinoma, metastatic, NOS	2	3	5
C229	8170/3	Hepatocellular carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	1	0	1
	8170/3	Hepatocellular carcinoma, NOS	1	0	1
C23-C24	Gall bladder & Unspecified parts of biliary tract		9	7	16
C23	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C240	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
C241	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C249	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
	8160/3	Cholangiocarcinoma	0	1	1
C25	Pancreas		13	15	28
C250	8010/3	Carcinoma, NOS	1	2	3
	8140/3	Adenocarcinoma, NOS	2	2	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
	8441/3	Serous cystadenocarcinoma, NOS	1	0	1
	8585/3	Thymoma, type B3, malignant	1	0	1
C251	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C252	8140/3	Adenocarcinoma, NOS	1	0	1
	8452/3	Solid pseudopapillary carcinoma	0	1	1
	8800/3	Sarcoma, NOS	0	1	1
C253	8140/3	Adenocarcinoma, NOS	2	0	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
	8574/3	Adenocarcinoma with neuroendocrine differentiation	0	1	1
C254	8246/3	Neuroendocrine carcinoma, NOS	0	1	1
C259	8140/3	Adenocarcinoma, NOS	4	2	6
C30-C31	Nasal cavity & Accessory sinuses		6	3	9
C300	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	0	1	1
	8900/3	Rhabdomyosarcoma, NOS	0	1	1
C301	8070/3	Squamous cell carcinoma, NOS	1	0	1
C310	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	9220/3	Chondrosarcoma, NOS	1	0	1
	9679/6	Mediastinal large B-cell, diffuse, NOS	1	0	1
C313	8806/3	Desmoplastic small round cell tumor	0	1	1


TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C32	Larynx		16	1	17
C320	8070/3	Squamous cell carcinoma, NOS	9	1	10
C321	8070/3	Squamous cell carcinoma, NOS	5	0	5
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C329	8070/3	Squamous cell carcinoma, NOS	1	0	1
C33-C34	Trachea, Bronchus & Lung		109	95	204
C33	8010/3	Carcinoma, NOS	0	1	1
C340	8010/3	Carcinoma, NOS	3	0	3
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8046/3	Non-small cell carcinoma	3	1	4
	8046/6	Non-small cell carcinoma, metastatic	1	1	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	2	4	6
	8140/6	Adenocarcinoma, metastatic, NOS	1	3	4
C341	8010/3	Carcinoma, NOS	4	0	4
	8010/6	Carcinoma, metastatic, NOS	3	1	4
	8046/3	Non-small cell carcinoma	5	5	10
	8046/6	Non-small cell carcinoma, metastatic	1	1	2
	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8140/3	Adenocarcinoma, NOS	4	6	10
	8140/6	Adenocarcinoma, metastatic, NOS	3	1	4
C342	8010/3	Carcinoma, NOS	1	0	1
	8130/3	Transitional cell carcinoma, micropapillary	1	0	1
	8046/3	Non-small cell carcinoma	0	1	1
C343	8010/3	Carcinoma, NOS	2	1	3
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8046/3	Non-small cell carcinoma	0	2	2
	8046/6	Non-small cell carcinoma, metastatic	1	3	4
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	3	3	6
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C349	8010/3	Carcinoma, NOS	6	2	8
	8010/6	Carcinoma, metastatic, NOS	7	3	10
	8130/6	Transitional cell carcinoma, micropapillary, metastatic	0	1	1
	8046/3	Non-small cell carcinoma	7	5	12
	8046/6	Non-small cell carcinoma, metastatic	6	4	10
	8070/3	Squamous cell carcinoma, NOS	5	2	7
	8140/3	Adenocarcinoma, NOS	10	19	29
	8140/6	Adenocarcinoma, metastatic, NOS	25	20	45
	8240/3	Carcinoid tumor, NOS	0	1	1
	9060/3	Dysgerminoma	1	0	1
C37-C38	Intrathoracic organs		8	2	10
C37	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8252/3	Bronchiolo-alveolar carcinoma, non-mucinous	1	0	1
	8582/3	Thymoma, type AB, malignant	1	0	1
	8583/3	Thymoma, type B1, malignant	0	1	1
C381	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	9085/3	Mixed germ cell tumor	3	0	3
C383	9085/3	Mixed germ cell tumor	1	0	1

**TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022**

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C40-C41	Bone & Articular cartilage		7	7	14
C402	8801/3	Spindle cell sarcoma	2	2	4
	8851/3	Liposarcoma, well differentiated	1	0	1
	9180/3	Osteosarcoma, NOS	2	1	3
	9230/3	Chondroblastoma, malignant	1	0	1
	9250/3	Giant cell tumor of bone, malignant	0	1	1
C410	9180/3	Osteosarcoma, NOS	0	1	1
C414	9180/6	Osteosarcoma, metastatic NOS	0	1	1
	9220/3	Chondrosarcoma, NOS	0	1	1
C419	9260/6	Ewing sarcoma, metastatic	1	0	1
C43-C44	Skin		25	33	58
C432	8720/3	Malignant melanoma, NOS	0	1	1
C435	8720/3	Malignant melanoma, NOS	0	1	1
	8720/6	Malignant melanoma, metastatic, NOS	0	1	1
C436	8720/3	Malignant melanoma, NOS	2	0	2
C437	8720/3	Malignant melanoma, NOS	0	1	1
	8720/6	Malignant melanoma, metastatic, NOS	0	1	1
C439	8720/3	Malignant melanoma, NOS	0	1	1
C440	8070/3	Squamous cell carcinoma, NOS	1	1	2
C441	8010/3	Carcinoma, NOS	0	1	1
	8090/3	Basal cell carcinoma, NOS	2	1	3
C442	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8090/3	Basal cell carcinoma, NOS	1	0	1
C443	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	2	4
	8090/3	Basal cell carcinoma, NOS	3	7	10
C444	8010/6	Carcinoma, metastatic, NOS	0	1	1
C445	8070/3	Squamous cell carcinoma, NOS	0	1	1
C446	8801/3	Spindle cell sarcoma	0	1	1
C447	9130/3	Hemangioendothelioma, malignant	1	0	1
C448	8070/3	Squamous cell carcinoma, NOS	0	1	1
C449	8010/3	Carcinoma, NOS	1	0	1
	8020/3	Carcinoma, undifferentiated, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	6	1	7
	8090/3	Basal cell carcinoma, NOS	2	6	8
	8140/3	Adenocarcinoma, NOS	0	1	1
	8542/3	Paget disease, extramammary	0	1	1
	8542/3	Paget disease, extramammary	1	0	1
	8810/3	Fibrosarcoma, NOS	1	0	1
C45 – C49	Mesothelial & Soft tissue		12	14	26
C450	9050/3	Mesothelioma, malignant	1	0	1
C451	8720/3	Malignant melanoma, NOS	0	1	1
C480	8890/3	Leiomyosarcoma, NOS	1	0	1
C490	8800/3	Sarcoma, NOS	1	1	2
	8832/3	Dermatofibrosarcoma, NOS	1	0	1
	9120/3	Hemangiosarcoma	1	0	1
C491	8010/3	Carcinoma, NOS	0	1	1
	8801/3	Spindle cell sarcoma	0	1	1
C492	8800/3	Sarcoma, NOS	1	1	2
	8801/3	Spindle cell sarcoma	1	2	3



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
	8802/3	Giant cell sarcoma	0	1	1
	8805/3	Undifferentiated sarcoma	1	0	1
	8810/3	Fibrosarcoma, NOS	0	2	2
	8851/3	Liposarcoma, well differentiated	2	0	2
	8858/3	Dedifferentiated liposarcoma	0	1	1
	9040/3	Synovial sarcoma, NOS	1	0	1
C494	8004/3	Malignant tumor, spindle cell type	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
C496	9040/3	Synovial sarcoma, NOS	0	1	1
C499	8850/3	Liposarcoma, NOS	0	1	1
C50	Breast		5	219	224
C500	8010/3	Carcinoma, NOS	0	2	2
	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8500/3	Infiltrating duct carcinoma, NOS	0	14	14
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	2	2
C501	8010/3	Carcinoma, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	5	5
C502	8500/3	Infiltrating duct carcinoma, NOS	0	3	3
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
C503	8010/3	Carcinoma, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	1	1
C504	8500/3	Infiltrating duct carcinoma, NOS	0	12	12
	8800/3	Sarcoma, NOS	0	1	1
C505	8500/3	Infiltrating duct carcinoma, NOS	0	2	2
C509	8010/3	Carcinoma, NOS	0	4	4
	8010/6	Carcinoma, metastatic, NOS	0	4	4
	8046/3	Non-small cell carcinoma	1	0	1
	8050/3	Papillary carcinoma, NOS	0	2	2
	8140/3	Adenocarcinoma, NOS	0	1	1
	8480/3	Mucinous adenocarcinoma	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	3	147	150
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	12	12
	8801/6	Spindle cell sarcoma, metastatic	0	1	1
	9500/3	Neuroblastoma, NOS	1	0	1
C51,C52,C57	Female genital organs		0	6	6
C510	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	2	2
C512	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	0	1	1
C52	8140/3	Adenocarcinoma, NOS	0	1	1
C570	8010/3	Carcinoma, NOS	0	1	1


TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C53	Cervix		0	51	51
C530	8010/3	Carcinoma, NOS	0	2	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	8	8
C531	8070/3	Squamous cell carcinoma, NOS	0	20	20
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	2	2
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	2	2
	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	0	6	6
	8140/3	Adenocarcinoma, NOS	0	1	1
C539	8010/3	Carcinoma, NOS	0	2	2
	8070/3	Squamous cell carcinoma, NOS	0	3	3
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	2	2
C54	Corpus uteri		0	43	43
C541	8010/3	Carcinoma, NOS	0	10	10
	8140/3	Adenocarcinoma, NOS	0	8	8
	8180/3	Combined hepatocellular carcinoma and cholangiocarcinoma	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	15	15
	8380/6	Endometrioid adenocarcinoma, metastatic, NOS	0	3	3
	8441/3	Serous cystadenocarcinoma, NOS	0	2	2
	8800/3	Sarcoma, NOS	0	1	1
	8980/3	Carcinosarcoma, NOS	0	2	2
C542	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
C55	Uterus		0	2	2
C55	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
	8801/3	Spindle cell sarcoma	0	1	1
C56	Ovary		0	28	28
C56	8010/3	Carcinoma, NOS	0	8	8
	8140/3	Adenocarcinoma, NOS	0	3	3
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
	8310/3	Clear cell adenocarcinoma, NOS	0	5	5
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
	8441/3	Serous cystadenocarcinoma, NOS	0	2	2
	8441/6	Serous cystadenocarcinoma, metastatic, NOS	0	1	1
	8471/3	Papillary mucinous cystadenocarcinoma	0	1	1
	8980/3	Carcinosarcoma, NOS	0	2	2
	9060/3	Dysgerminoma	0	1	1
D391	8480/6	Mucinous adenocarcinoma, metastatic	0	1	1
C60, C62-C63	Male genital organs		6	0	6
C600	8070/3	Squamous cell carcinoma, NOS	1	0	1
C601	8010/3	Carcinoma, NOS	1	0	1
C609	8070/3	Squamous cell carcinoma, NOS	1	0	1
C629	9061/3	Seminoma, NOS	2	0	2
	9085/3	Mixed germ cell tumor	1	0	1

2022 HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C61	Prostate gland		112	0	112
C61	8010/6	Carcinoma, metastatic, NOS	2	0	2
	8140/3	Adenocarcinoma, NOS	100	0	100
	8140/6	Adenocarcinoma, metastatic, NOS	10	0	10
C64-C66	Kidney, Renal pelvis & Ureter		25	7	32
C64	8010/3	Carcinoma, NOS	2	1	3
	8010/6	Carcinoma, metastatic, NOS	4	0	4
	8140/3	Adenocarcinoma, NOS	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	4	1	5
	8312/3	Renal cell carcinoma, NOS	10	1	11
	8312/6	Renal cell carcinoma, metastatic, NOS	3	1	4
	8720/3	Malignant melanoma, NOS	1	0	1
C65	8010/3	Carcinoma, NOS	1	1	2
C66	8010/3	Carcinoma, NOS	0	1	1
C67	Bladder		28	5	33
C670	8010/3	Carcinoma, NOS	3	0	3
	8130/3	Transitional cell carcinoma, micropapillary	5	0	5
C671	8010/3	Carcinoma, NOS	1	0	1
C672	8130/3	Transitional cell carcinoma, micropapillary	1	0	1
	8130/3	Transitional cell carcinoma, micropapillary	2	1	3
C674	8010/3	Carcinoma, NOS	0	1	1
	8130/3	Transitional cell carcinoma, micropapillary	2	0	2
C679	8010/3	Carcinoma, NOS	8	1	9
	8010/6	Carcinoma, metastatic, NOS	1	1	2
	8130/3	Transitional cell carcinoma, micropapillary	4	1	5
	8140/3	Adenocarcinoma, NOS	1	0	1
C68	Other and unspecified urinary organs		0	1	1
C680	8010/3	Carcinoma, NOS	0	1	1
C69-C70	Eye & Meninges		0	1	1
C695	8140/3	Adenocarcinoma, NOS	0	1	1
C71	Brain		6	9	15
C712	9380/3	Glioma, malignant	0	1	1
C713	9392/3	Ependymoma, anaplastic	0	1	1
C719	8720/3	Malignant melanoma, NOS	0	2	2
	9064/3	Germinoma	1	0	1
	9380/3	Glioma, malignant	2	1	3
	9382/3	Mixed glioma	1	0	1
	9400/3	Astrocytoma, NOS	0	1	1
	9401/3	Astrocytoma, anaplastic	1	0	1
	9440/6	Glioblastoma, metastatic, NOS	1	0	1
	9530/3	Meningioma, malignant	0	1	1
	9537/3	Transitional meningioma	0	1	1
C720	9560/3	Neurilemoma, malignant	0	1	1

**TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022**

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C73	Thyroid gland		18	85	103
C73	8010/3	Carcinoma, NOS	2	5	7
	8010/6	Carcinoma, metastatic, NOS	2	0	2
	8050/3	Papillary carcinoma, NOS	9	67	76
	8050/6	Papillary carcinoma, metastatic, NOS	2	0	2
	8260/3	Papillary adenocarcinoma, NOS	1	4	5
	8330/3	Follicular adenocarcinoma, NOS	1	0	1
	8335/3	Follicular carcinoma, minimally invasive	0	1	1
	8335/6	Follicular carcinoma, minimally invasive, metastatic	1	0	1
	8341/3	Papillary microcarcinoma	0	8	8
C74	Adrenal gland		2	0	2
C749	8700/3	Pheochromocytoma, malignant	1	0	1
	9364/3	Peripheral neuroectodermal tumor	1	0	1
C75-C79	Other endocrine glands and relate structures		8	3	11
C751	8720/3	Malignant melanoma, NOS	0	1	1
C759	8010/3	Carcinoma, NOS	1	0	1
C765	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C770	8010/3	Carcinoma, NOS	1	0	1
C780	8140/3	Adenocarcinoma, NOS	1	0	1
	8720/3	Malignant melanoma, NOS	1	0	1
C782	8140/3	Adenocarcinoma, NOS	0	1	1
C787	8010/3	Carcinoma, NOS	1	0	1
C790	8130/3	Transitional cell carcinoma, micropapillary	0	1	1
C793	8010/6	Carcinoma, metastatic, NOS	1	0	1
C795	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C80	Without specification of site		3	0	3
C800	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
C809	8806/3	Desmoplastic small round cell tumor	1	0	1
C81	Hodgkin's lymphoma		4	2	6
C81	9650/3	Hodgkin lymphoma, NOS	0	1	1
C811	9650/3	Hodgkin lymphoma, NOS	1	1	2
C817	9650/3	Hodgkin lymphoma, NOS	1	0	1
C819	9591/3	Malignant lymphoma, non-Hodgkin, NOS	1	0	1
	9650/3	Hodgkin lymphoma, NOS	1	0	1
C82-C88	Non - Hodgkin's lymphoma		30	31	61
C823	9695/3	Follicular lymphoma, grade 1	0	1	1
C830	9591/3	Malignant lymphoma, non-Hodgkin, NOS	0	1	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C831	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C833	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	8	4	12
	9596/6	Composite Hodgkin and non-Hodgkin lymphoma, metastatic	1	1	2
	9650/3	Hodgkin lymphoma, NOS	0	1	1
	9671/3	Malignant lymphoma, lymphoplasmacytic	1	0	1
	9680/3	Malignant lymphoma, large B-cell , diffuse, NOS	4	2	6
	9680/6	Malignant lymphoma, large B-cell , diffuse, metastatic, NOS	1	1	2


TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2022

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
	9680/3	Malignant lymphoma, large B-cell , diffuse, NOS	1	1	2
	9714/3	Anaplastic large cell lymphoma, T cell and Null cell type	1	0	1
C84	9702/3	Mature T-cell lymphoma, NOS	0	1	1
C840	9702/3	Mature T-cell lymphoma, NOS	0	1	1
C844	9590/3	Malignant lymphoma, NOS	0	1	1
	9702/3	Mature T-cell lymphoma, NOS	0	2	2
C8449	9827/3	Adult T-cell leukemia/lymphoma	0	1	1
C846	8010/6	Carcinoma, metastatic, NOS	1	0	1
	9695/3	Follicular lymphoma, grade 1	0	1	1
C851	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
	9680/3	Malignant lymphoma, large B-cell , diffuse, NOS	1	1	2
	9680/6	Malignant lymphoma, large B-cell , diffuse, metastatic, NOS	1	0	1
C859	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	3	3	6
	9680/3	Malignant lymphoma, large B-cell , diffuse, NOS	0	2	2
C863	9702/3	Mature T-cell lymphoma, NOS	1	0	1
	9835/3	Precursor cell lymphoblastic leukemia, NOS	1	0	1
C884	9673/6	Mantle cell lymphoma	0	1	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
	9680/3	Malignant lymphoma, large B-cell , diffuse, NOS	1	1	2
	9699/3	Marginal zone B-cell lymphoma, NOS	3	1	4
C90	Multiple myeloma		16	9	25
C900	9732/3	Multiple myeloma	15	8	23
C902	8720/3	Malignant melanoma, NOS	0	1	1
	9590/3	Malignant lymphoma, NOS	1	0	1
C910	9801/3	Acute leukemia, NOS	0	1	1
	9835/3	Precursor cell lymphoblastic leukemia, NOS	4	4	8
	9835/6	Precursor cell lymphoblastic leukemia, metastatic, NOS	0	1	1
C911	9823/3	B-cell chronic lymphocytic leukemia/small lymphoma	2	0	2
C919	9801/3	Acute leukemia, NOS	1	0	1
C920	9861/3	Acute myeloid leukemia, NOS	1	0	1
	9801/3	Acute leukemia, NOS	2	0	2
	9861/3	Acute myeloid leukemia, NOS	6	8	14
C921	9863/3	Chronic myeloid leukemia, NOS	0	1	1
	9860/3	Myeloid leukemia, NOS	1	0	1
	9861/3	Acute myeloid leukemia, NOS	0	1	1
	9863/3	Chronic myeloid leukemia, NOS	2	0	2
C924	9835/3	Precursor cell lymphoblastic leukemia, NOS	0	1	1
C946	9987/3	Therapy-related myelodysplastic syndrome, NOS	1	1	2
C950	9801/3	Acute leukemia, NOS	1	0	1
	9835/3	Precursor cell lymphoblastic leukemia, NOS	0	1	1
	9861/3	Acute myeloid leukemia, NOS	1	1	2
	9948/3	Aggressive NK-cell leukemia	1	0	1
C965	9835/3	Precursor cell lymphoblastic leukemia, NOS	0	1	1
D469	9989/3	Myelodysplastic syndrome, NOS	1	0	1
D474	9931/3	Acute panmyelosis with myelofibrosis	0	1	1
D613	9961/3	Myelofibrosis with myeloid metaplasia	0	1	1



New cancer patients 2018-2022

TABLE 67

DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP AND GENDER: 2018-2022

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2358	56.8	2960	72.7	5318	64.7
Deaths	1795	43.2	1109	27.3	2904	35.3
Total	4153	100.0	4069	100.0	8222	100.0

Survey: 5 April 2022

TABLE 68

THE LEADING PRIMARY SITES OF NEW CANCER BY GENDER: 2018-2022

Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Breast	10	0.2	1008	24.8	1018	12.4
2	Colon & Rectum	605	14.6	400	9.8	1005	12.2
3	Trachea, bronchus and lung	581	14.0	377	9.3	958	11.7
4	Liver and intrahepatic bile ducts	482	11.6	131	3.2	613	7.5
5	Thyroid gland	100	2.4	411	10.1	511	6.2
6	Prostate gland	463	11.1	0	0.0	463	5.6
7	Non-Hodgkin's lymphoma	223	5.4	200	4.9	423	5.1
8	leukaemia	150	3.6	110	2.7	260	3.2
9	Cervix	0	0.0	240	5.9	240	2.9
10	Skin	103	2.5	117	2.9	220	2.7

Survey: 5 April 2022



TABLE 69 THE LEADING PRIMARY SITES OF NEW CANCER BY FOLLOW UP AND GENDER: 2018-2022						
Ordinal	Primary site	Alive		Deaths		Total
		Male	Female	Male	Female	
1	Breast	10	872	0	136	1018
2	Colon & Rectum	414	295	191	105	1005
3	Trachea, bronchus & lung	193	185	388	192	958
4	Liver & intrahepatic bile ducts	182	44	300	87	613
5	Thyroid gland	91	394	9	17	511
6	Prostate gland	384	0	79	0	463
7	Non-Hodgkin's lymphoma	139	148	84	52	423
8	leukaemia	69	55	81	55	260
9	Cervix	0	174	0	66	240
10	Skin	83	94	20	23	220

Survey: 5 April 2022

TABLE 70 THE 60 MONTHS SURVIVAL TIME (MEDIAN) TOP 6 BY GENDER IN 2018 - 2022			
Ordinal	Primary site	Male	Female
1	Breast	5.00	6.65
2	Colon & Rectum	11.14	10.00
3	Trachea, bronchus & lung	5.02	7.14
4	Liver & intrahepatic bile ducts	4.71	5.08
5	Thyroid gland	13.34	14.52
6	Prostate gland	6.50	0.00

Survey: 5 April 2022





HOSPITAL-BASED CANCER REGISTRY **2022**

ANNUAL REPORT

FIGURE 32: THE 60 MONTHS SURVIVAL RATE (TOP 6) IN 2018 – 2022







FIGURE 33: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY MALE IN 2018 – 2022







HOSPITAL-BASED CANCER REGISTRY 2022

ANNUAL REPORT

FIGURE 34: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY FEMALE IN 2018–2022



Phramongkutklao Hospital 315 Ratchawithi Rd, Bangkok 10400 Thailand.





PHRAMONGKUTKLAO HOSPITAL

EXCELLENT CENTER
OF CANCER CARE

2022

Oncology Unit and Epidemiology Unit,
Phramongkutklao Hospital.

315 Ratchawithi Road, Bangkok 10400, Thailand.

Tel. : + 66 2763 3925, + 66 2763 3047

Email : ceupmk@hotmail.com

Website : <http://ceu.pmk.ac.th>